ESSA Total Liab from 2010 to 2024
| EPIX Stock | USD 5.77 0.35 5.72% |
Total Liabilities | First Reported 2013-09-30 | Previous Quarter 4.4 M | Current Value 3.8 M | Quarterly Volatility 4.1 M |
Check ESSA Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ESSA Pharma's main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 5.9 K or Selling General Administrative of 7.6 M, as well as many indicators such as Price To Sales Ratio of 272.8 K, Dividend Yield of 0.0 or PTB Ratio of 52.01. ESSA financial statements analysis is a perfect complement when working with ESSA Pharma Valuation or Volatility modules.
ESSA | Total Liab |
Latest ESSA Pharma's Total Liab Growth Pattern
Below is the plot of the Total Liab of ESSA Pharma over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. ESSA Pharma's Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ESSA Pharma's overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
ESSA Total Liab Regression Statistics
| Arithmetic Mean | 3,915,907 | |
| Geometric Mean | 842,706 | |
| Coefficient Of Variation | 84.79 | |
| Mean Deviation | 2,485,465 | |
| Median | 3,495,071 | |
| Standard Deviation | 3,320,334 | |
| Sample Variance | 11T | |
| Range | 10.9M | |
| R-Value | 0.26 | |
| Mean Square Error | 11.1T | |
| R-Squared | 0.07 | |
| Significance | 0.36 | |
| Slope | 190,259 | |
| Total Sum of Squares | 154.3T |
ESSA Total Liab History
About ESSA Pharma Financial Statements
ESSA Pharma investors use historical fundamental indicators, such as ESSA Pharma's Total Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in ESSA Pharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 4 M | 4.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| AVAV | AeroVironment | |
| ELVN | Enliven Therapeutics | |
| NFLX | Netflix |
Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.